Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab to Present at 19th Annual Piper Jaffray Health Care Conference19 Nov 2007
Genmab to Present HuMax-IL8 Pre-clinical Data16 Nov 2007
Genmab to Present Zanolimumab and Ofatumumab Data at ASH9 Nov 2007
Interim Report for the 9 months ended September 30, 200730 Oct 2007
Genmab Announces Results for the First Nine Months of 200730 Oct 2007
Genmab A/S Articles of Association dated October 4, 200725 Oct 2007
Phase I Results Announced for R1507 from Genmab's Collaboration with Roche23 Oct 2007
Genmab's HuMax-CD4 Displays Unique Mechanism of Action
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
15 Oct 2007
Genmab Amends HuMax-CD4 Pivotal Study in CTCL11 Oct 2007
Grant of Warrants in Genmab A/S4 Oct 2007
Roche Files CTA for Third Genmab Antibody2 Oct 2007
Genmab to Attend Two October Investor Conferences1 Oct 2007
  • Previous
  • 1
  • More pages
  • 116
  • 117
  • 118
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863